Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 08:42 ET | Source: Ipsen Pharma

Ipsen présentera, lors de deux sessions « late-breaking » au congrès de l’AASLD, de nouvelles données sur la CBP confirmant l’efficacité et la tolérance à long terme d’IQIRVO® ainsi que de nouvelles analyses sur les mécanismes sous-jacents

Les données intermédiaires de l’étude d’extension ouverte à long terme ELATIVE évaluant IQIRVO® (élafibranor) démontrent une réponse biochimique soutenue, une stabilisation des marqueurs de fibrose et...
November 07, 2025 08:42 ET | Source: Ipsen Pharma

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Interim data from the IQIRVO® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in...
October 22, 2025 08:00 ET | Source: Aptera Motors Corp

Aptera Motors Transitions to Public Benefit Corporation, Adds Industry Veterans to Board

Aptera Motors Corp. today announced its formal transition to a Public Benefit Corporation (PBC) under Delaware law.
July 17, 2025 13:00 ET | Source: Spherix Global Insights

GSK’s Linerixibat Poised to Address Substantial Unmet Need for the Treatment of Pruritus Associated with Primary Biliary Cholangitis, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of...
November 27, 2024 04:30 ET | Source: Advanz Pharma

ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe

ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The conditional marketing authorisation...
September 05, 2024 02:35 ET | Source: Advanz Pharma

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The European Commission’s decision to revoke the OCALIVA®...
September 03, 2024 04:00 ET | Source: Advanz Pharma

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC)

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...
August 29, 2024 14:14 ET | Source: Spherix Global Insights

Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi

EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
January 15, 2020 06:00 ET | Source: Imaging3, Inc.

Grapefruit/IGNG and Pacific Banking Corp Announce Signing a Reseller Letter of Intent to Expand Cannabis Banking Services into Southern California.

Los Angeles & Desert Hot Springs, California, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Grapefruit Boulevard Investments, Inc., (“GBI”) a licensed and fully compliant California based cannabis...
February 02, 2017 10:00 ET | Source: Premier Boxing Champions, Al Haymon Boxing

Premier Boxing Champions Series Opens 2017 With a Smash

Next Five Weeks Includes Two Blockbuster Primetime Network Shows The Return of Heavyweight Champion Deontay Wilder; and Welterweight Mega-Fight Between Champions Danny Garcia and Keith Thurman LAS...